Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Potier

Showing results (11-20 of 97) with videos related to

Pageof 10
Sort By:
Diabetes, Obesity & Metabolism|June 10, 2017
Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventionsRonan Roussel, Philippe Gabriel Steg, Kamel Mohammedi, et al.
Diabetes, Obesity & Metabolism|March 4, 2023
Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational studyKamel Mohammedi, Narimene Belhatem, Tina Landsvig Berentzen, et al.
Biological Chemistry|January 18, 2013
Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiencyLouis Potier, Ludovic Waeckel, Christine Richer, et al.
Current Pharmaceutical Design|July 7, 2011
Kinins as therapeutic agents in cardiovascular and renal diseasesFrancois Alhenc-Gelas, Nadine Bouby, Christine Richer, et al.
Diabetes Care|January 25, 2020
Chronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI ProgramLouis Potier, Ronan Roussel, Marianne Zeller, et al.
Journal of the American College of Cardiology|February 23, 2010
Cryoglobulin-induced cardiomyopathyAlexandre Karras, Louis Potier, Anne-Hélène Reboux, et al.
Biological Chemistry|September 14, 2016
Kallikrein(K1)-kinin-kininase (ACE) and end-organ damage in ischemia and diabetes: therapeutic implicationsDorinne Desposito, Ludovic Waeckel, Louis Potier, et al.
Advances in Therapy|December 5, 2024
Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc AnalysisGottfried Rudofsky, Markus Menzen, Louis Potier, et al.
Cardiovascular Diabetology|January 9, 2016
Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetesKamel Mohammedi, Louis Potier, Narimène Belhatem, et al.
Endocrinology|June 7, 2012
Antihypertensive role of tissue kallikrein in hyperaldosteronism in the mouseLudovic Waeckel, Louis Potier, Catherine Chollet, et al.
Pageof 10

Showing results (11-20 of 97) with videos related to

Sort By:
Pageof 10
Diabetes, Obesity & Metabolism|June 10, 2017
Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventionsRonan Roussel, Philippe Gabriel Steg, Kamel Mohammedi, et al.
Diabetes, Obesity & Metabolism|March 4, 2023
Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational studyKamel Mohammedi, Narimene Belhatem, Tina Landsvig Berentzen, et al.
Biological Chemistry|January 18, 2013
Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiencyLouis Potier, Ludovic Waeckel, Christine Richer, et al.
Current Pharmaceutical Design|July 7, 2011
Kinins as therapeutic agents in cardiovascular and renal diseasesFrancois Alhenc-Gelas, Nadine Bouby, Christine Richer, et al.
Diabetes Care|January 25, 2020
Chronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI ProgramLouis Potier, Ronan Roussel, Marianne Zeller, et al.
Journal of the American College of Cardiology|February 23, 2010
Cryoglobulin-induced cardiomyopathyAlexandre Karras, Louis Potier, Anne-Hélène Reboux, et al.
Biological Chemistry|September 14, 2016
Kallikrein(K1)-kinin-kininase (ACE) and end-organ damage in ischemia and diabetes: therapeutic implicationsDorinne Desposito, Ludovic Waeckel, Louis Potier, et al.
Advances in Therapy|December 5, 2024
Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc AnalysisGottfried Rudofsky, Markus Menzen, Louis Potier, et al.
Cardiovascular Diabetology|January 9, 2016
Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetesKamel Mohammedi, Louis Potier, Narimène Belhatem, et al.
Endocrinology|June 7, 2012
Antihypertensive role of tissue kallikrein in hyperaldosteronism in the mouseLudovic Waeckel, Louis Potier, Catherine Chollet, et al.
Pageof 10